Buy Like Buffett
Watchlist

Flagship explainer

How ADAPTIMMUNE THERAPEUTICS PLC makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$178M · 100%Cost of revenue$70000 · 0%Gross profit$178M · 100%Operating income−$68.8M · −39%Income before tax−$67.2M · −38%Income tax$3.6M · 2%Net income−$70.8M · −40%As of 2024-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$178M100%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
Cost of revenue$700000%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
$178M100%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
−$68.8M−39%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
Income before tax−$67.2M−38%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
Income tax$3.6M2%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
−$70.8M−40%
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
Source:
  • 10-K · FY 2024Filing detailsAccession 0001558370-25-003544 · filed Mar 24, 2025
· event Dec 31, 2024 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

View the full ADAPTIMMUNE THERAPEUTICS PLC analysis at Buy Like Buffett